BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Research and development spending
3Y CAGR
-13.1%/yr
vs +31.4%/yr prior
5Y CAGR
+6.2%/yr
Recent deceleration
Acceleration
-44.5pp
Decelerating
Percentile
P71
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
3 yr
Consecutive declineStable
| Period | Value | YoY Change |
|---|---|---|
| TTM | $166.13M | -4.9% |
| 2024 | $174.64M | -19.4% |
| 2023 | $216.57M | -14.5% |
| 2022 | $253.30M | +21.3% |
| 2021 | $208.81M | +69.8% |
| 2020 | $122.96M | +14.8% |
| 2019 | $107.07M | +26.1% |
| 2018 | $84.89M | +26.8% |
| 2017 | $66.96M | +9.8% |
| 2016 | $61.01M | - |